---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009898"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:45.212693+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dianthus expects ~$514M cash at year-end 2025; CEO to present at JPM conference

## Summary
- Preliminary unaudited cash, cash equivalents, and short-term investments of ~$514M as of Dec 31, 2025.
- Actual results may differ materially due to completion of financial closing procedures.
- CEO Marino Garcia to present at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.
- Presentation focuses on advancing the autoimmune-focused pipeline.

## SEC filing metadata
- accession: 0001193125-26-009898
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/0001193125-26-009898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009898
- JSON: https://secwatch.observer/filing/0001193125-26-009898.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.